Chemotherapy + bevacizumab leads to higher overall tumour response compared with chemotherapy (high certainty).
Chemotherapy + bevacizumab showed no clear difference in severe adverse effects compared with chemotherapy (low certainty).
Modern chemotherapy regimens probably leads to lower overall survival compared with 5‐flourouracil (moderate certainty).
Modern chemotherapy regimens leads to lower progression‐free survival compared with 5‐flourouracil (high certainty).
Modern chemotherapy regimens leads to higher overall tumour response compared with 5‐flourouracil (high certainty).
Modern chemotherapy regimens probably leads to higher severe adverse effects compared with 5‐flourouracil (moderate certainty).
Oral showed no clear difference in disease‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
It is very uncertain whether oral changes grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (very low certainty).
Oral may leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (low certainty).
Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).
Oral probably leads to higher progression‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
Oral may leads to higher grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (low certainty).
Oral probably leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (moderate certainty).
Adjunctive Coriolus versicolor may leads to higher survival ‐ compared with no adjunctive treatment (low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes withdrawal from treatment due to adverse events ‐ compared with no adjunctive treatment (very low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Oral cavity disorders (includes oral dryness and… compared with no adjunctive treatment (very low certainty).
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Nausea ‐ compared with no adjunctive treatment (very low certainty).